Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Vaccine Remove
Related Tags


March 2015
Su Sa Fr Th We Tu Mo
1
February 2015
28 27 26 25 24 23

vaccine Press Releases

  + XML/RSS  



By Visiongain
LONDON, UK, 14th November 2014: A new report by visiongain calculates that the global market for diagnostic tools, preventative vaccines and therapeutic drugs targeting Ebola will achieve significant growth in the coming years.
By WebFL.US
Some say the deadly Ebola virus is unstoppable and the privacy-killing UID your ISP may be injecting into your web traffic is unblockable but a Miami web development firm just verified its antidote for one of them.
By GMR Data
The Global Pre-filled Syringe Market 2014-2024 is GMR Data’s latest pharma report, covering the pharmaceutical, commercial and strategic developments in the global pre-filled syringe market.
By Shiva Science & Technology Group LLC
Shiva's NISP vaccine platform can make it possible to begin wide distribution of an Ebola vaccine before next May
By Gold Law Firm LLC
Vaccines are safe, Federal Program Exists to Help those Injured.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization
By SMi Group
Cancer Vaccines 2014; Quantify Strategies to Enhance Cancer Vaccine Research and Development, 15th - 16 September, London UK
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells
By Strategic Book Publishing and Rights Co, LLC
Strategic Book Publishing & Rights Agency is pleased to announce the release of its newest title, The Divergence Conspiracy, by author Keith Bottin.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces NeuroVax Granted Fast Track FDA Designation for SPMS
By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.
By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.
By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.
By SMi Group
Development, manufacture and regulation of pre-filled syringes and injector devices: presentations from Merck, Pfizer, Roche, Medimmune and others
By Kansas City Star Books
Kansas Journalist Andy Marso Chronicles Long Road Back to Health in New Book "Worth the Pain: How Meningitis Nearly Killed Me--Then Changed My Life for the Better"
By SMI Group
SMi's announce record breaking attendance at Cancer Vaccines 2013 which returns in 2 weeks.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.
By SMi Group
Vivavacs SAS to Present at 2013 Cancer Vaccines Summit, London
By The Arizona Partnership for Immunization
The Arizona Partnership for Immunization (TAPI) honored 61 individuals, organizations, and initiatives during the 17th Annual Arizona Big Shots awards dinner held on April 17, 2013 at the Phoenix Country Club. Over 325 people attended the event.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

All Press Releases

By Visiongain
LONDON, UK, 3rd of February 2015: A new report by visiongain forecasts overall human vaccines revenue will reach $56.38bn worldwide in 2019.
By Immune Response BioPharma
Immune Response BioPharma, Inc. Announces REMUNE FDA BLA Assignment PDUFA Goal date of December 22nd 2015 for Therapeutic HIV/AIDS Vaccine
By Alcimed
An overview of opportunities and threats of therapeutic vaccines
By Bergen Mama
So far, 2015 isn’t getting off to the healthiest start. In addition to a particularly nasty flu season, there have been 102 cases of measles in 14 states to date, putting us on track to see the highest number of infections in the U.S.
By IMMUNE RESPONSE BIOPHARMA INC
Immune Response BioPharma, Inc. Files BLA with the FDA for REMUNE HIV/AIDS Vaccine Marketing Approval for Therapeutic HIV/AIDS Vaccination
By Gold Law Firm LLC
Massachusetts Law Firm Settles Flu Vaccine Injury Petition under the National Vaccine Injury Compensation Program. Many are not aware of Compensation Program and the short, strict deadlines that must be met in order to qualify.
By porkchop publishing
The author’s father came down with polio during the epidemic of 1944. This book describes his story of pain, rehabilitation and return to normality as well as inspirational stories of other polio survivors, some more severely paralyzed than he was.
By Visiongain
LONDON, UK, 14th November 2014: A new report by visiongain calculates that the global market for diagnostic tools, preventative vaccines and therapeutic drugs targeting Ebola will achieve significant growth in the coming years.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Files REMUNE Pediatric HIV/AIDS Phase II Study Protocol with the FDA for Breakthrough Designation
By WebFL.US
Some say the deadly Ebola virus is unstoppable and the privacy-killing UID your ISP may be injecting into your web traffic is unblockable but a Miami web development firm just verified its antidote for one of them.
By GMR Data
The Global Pre-filled Syringe Market 2014-2024 is GMR Data’s latest pharma report, covering the pharmaceutical, commercial and strategic developments in the global pre-filled syringe market.
By Shiva Science & Technology Group LLC
In an email to the WHO, Shiva Science & Technology Group (www.ShivaSTG.com) made an offer that few in the pharmaceutical industry would.
By Shiva Science & Technology Group LLC
Shiva's NISP vaccine platform can make it possible to begin wide distribution of an Ebola vaccine before next May
By Gold Law Firm LLC
Vaccines are safe, Federal Program Exists to Help those Injured.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization
By SMi Group
Cancer Vaccines 2014; Quantify Strategies to Enhance Cancer Vaccine Research and Development, 15th - 16 September, London UK
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells
By Strategic Book Publishing and Rights Co, LLC
Strategic Book Publishing & Rights Agency is pleased to announce the release of its newest title, The Divergence Conspiracy, by author Keith Bottin.
By Hemispherx Biopharma
Non-Human Primate Animal Testing Planned as This Deadly New Virus Now Reaches The United States and Southeast Asia, and Disease Incidence Accelerates
By Gold Law Firm LLC
National Law Firm Settles Flu Vaccine Injury Petition under the National Vaccine Injury Compensation Program. Many are not aware of Compensation Program and the short, strict deadlines that must be met in order to qualify.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces NeuroVax Granted Fast Track FDA Designation for SPMS
By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.
By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.
By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.
By PRN.FM
Bill Gates and the University of Pittsburgh data mining project to convince legislators to make the vaccination of all Americans mandatory.
By SMi Group
Development, manufacture and regulation of pre-filled syringes and injector devices: presentations from Merck, Pfizer, Roche, Medimmune and others
By American Academy of Neurology
A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis (MS) in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology®,...
By Kansas City Star Books
Kansas Journalist Andy Marso Chronicles Long Road Back to Health in New Book "Worth the Pain: How Meningitis Nearly Killed Me--Then Changed My Life for the Better"
By PRN.fm
Gary Null & Richard Gale Progressive Radio Network, November 15, 2013
By visiongain
A new report by visiongain predicts that the world market for vaccines will reach $48bn in 2015. From this market, vaccine contract manufacturing will reach $0.62bn in 2015.
By Organization of Teratology Information Specialists
Tdap Vaccine During Pregnancy Provides Some Protection To Newborns
By SMI Group
SMi's announce record breaking attendance at Cancer Vaccines 2013 which returns in 2 weeks.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Fast Track & Orphan Designation of NeuroVax for SPMS to Expand Novel use of MS Vaccine Treatment
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc., has notified the MCC of South Africa that IRBP will Seek Emergency Approval of REMUNE in S.A. as well begin stockpiling & manufacturing the HIV/AIDS vaccine once we have secured a corporate partner in the region.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.
By SMi Group
Vivavacs SAS to Present at 2013 Cancer Vaccines Summit, London
By Fast Market Research, Inc.
Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs, states a new report by research and consulting firm GBI Research.
By The Arizona Partnership for Immunization
The Arizona Partnership for Immunization (TAPI) honored 61 individuals, organizations, and initiatives during the 17th Annual Arizona Big Shots awards dinner held on April 17, 2013 at the Phoenix Country Club. Over 325 people attended the event.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine
By NJ Aid for Animals
NJ Aid for Animals’ Delivers Lifesaving Vaccines for Camden Animals and Introduces “Lost No More” at its Spring...
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.
By RF Media
As part of the United Nations Foundation Shot@Life campaign, Lee Reyes-Fournier added her support to nearly 100 doctors, advocates and bloggers committed to seeing that every child in the world has a chance at life by receiving their vaccinations.
By Travel Safe Clinic
Biological E, one of the leading Indian vaccine manufacturers, has launched a safe and effective vaccine against Japanese Encephalitis, a deadly infectious disease and the leading cause of Acute Encephalitis.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.
By IMARC Group
The share of temperature sensitive healthcare products in the global healthcare market is expected to reach 23% by 2017.
By IMARC Group
The strong growth of the global biologicals market is expected to create a huge demand for efficient cold chain logistic services.
By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop Zorcell Psoriasis Vaccine the First Vaccine for Psoriasis & Reviews Phase II Results
By IMARC Group
A new report from IMARC Group expects the market for cold chain logistic services to grow at a CAGR of 8% during 2011-2017.
By Organization of Teratology Information Specialists
UNT Experts Available For Questions Regarding The Risk Of Meningitis Vaccine During Pregnancy
By Fast Market Research, Inc.
New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research


Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share